| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002888045 |
| P356 | DOI | 10.1038/SJ.LEU.2402106 |
| P698 | PubMed publication ID | 11368433 |
| P5875 | ResearchGate publication ID | 11970598 |
| P2093 | author name string | Chen J | |
| Tang W | |||
| Chen Z | |||
| Shen Y | |||
| Wu F | |||
| Wu W | |||
| Yan H | |||
| Wang ZY | |||
| Shen ZX | |||
| Chen SJ | |||
| Li JM | |||
| Li XS | |||
| Liu YF | |||
| Niu C | |||
| Xiong SM | |||
| Zeng XY | |||
| Zhao WL | |||
| P2860 | cites work | PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia | Q28343393 |
| Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents | Q28368953 | ||
| Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations | Q28375997 | ||
| Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient | Q33177365 | ||
| Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia | Q33178068 | ||
| The thrombophilic state in acute promyelocytic leukemia | Q33651721 | ||
| Current issues in the management of acute promyelocytic leukemia | Q33952291 | ||
| Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide | Q34478428 | ||
| New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation | Q41138385 | ||
| Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis | Q41735639 | ||
| Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells | Q42545311 | ||
| The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. | Q42551674 | ||
| Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia | Q77787329 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | arsenic | Q871 |
| arsenic trioxide | Q7739 | ||
| leukemia | Q29496 | ||
| acute promyelocytic leukemia | Q612108 | ||
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 735-741 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage | |
| P478 | volume | 15 |
| Q34591616 | Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia. |
| Q81014025 | Additional support for derivation of an acute/subchronic reference level for arsenic |
| Q34546653 | All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia |
| Q40617724 | Antitumor effect of arsenic trioxide in murine xenograft model |
| Q34715170 | Arsenic neurotoxicity--a review |
| Q36579412 | Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein |
| Q34171130 | Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells |
| Q35925650 | Arsenic trioxide in the treatment of haematological malignancies |
| Q34522507 | Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring |
| Q34435492 | Arsenic trioxide, a therapeutic agent for APL. |
| Q34588761 | Arsenic trioxide: safety issues and their management |
| Q33968624 | Arsenic(III) species inhibit oxidative protein folding in vitro |
| Q34545365 | Cardiac monitoring of patients receiving arsenic trioxide therapy |
| Q39378816 | Characterization of the role of protein-cysteine residues in the binding with sodium arsenite |
| Q38161360 | Differentiation therapy of acute myeloid leukemia. |
| Q53669938 | Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). |
| Q37696319 | Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9 |
| Q37929546 | Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia |
| Q40716128 | In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia |
| Q34591697 | Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains |
| Q34774164 | Management of acute promyelocytic leukemia |
| Q38108471 | Management of elderly patients with acute promyelocytic leukemia: progress and problems |
| Q34435576 | Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes |
| Q37776244 | Metalloid Transport by Aquaglyceroporins: Consequences in the Treatment of Human Diseases |
| Q34206010 | MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. |
| Q34978872 | Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression |
| Q36791537 | Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond. |
| Q35949253 | Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide |
| Q39158542 | Nona-copper(II)-containing 18-tungsto-8-arsenate(III) exhibits antitumor activity |
| Q39276978 | On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia |
| Q63859562 | Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice |
| Q26991440 | Perspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogs |
| Q24317497 | Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2 |
| Q98771238 | Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside |
| Q38198081 | Retiferols - synthesis and biological activity of a conceptually novel class of vitamin D analogs. |
| Q39484903 | Role of arsenic trioxide in acute promyelocytic leukemia |
| Q35800229 | Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient |
| Q37275674 | Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling |
| Q38522309 | Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. |
| Q34548159 | The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia |
| Q38089629 | The evolving use of arsenic in pharmacotherapy of malignant disease |
| Q35190480 | Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. |
| Q34575618 | Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies |
| Q39663601 | Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis |
| Q36340437 | YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide |
| Q85963373 | [Effect of arsenic trioxide on proliferation and apoptosis of human leukemia cell line MV4-11 cells] |
| Q35984023 | pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo. |
Search more.